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Abstract 
Using oligonucleotide primers derived from the vesicular monoamine transporters equences, a cDNA predicted to encode the bovine chromaffin 
granule amine transporter has been cloned (b-VMAT2). Surprisingly, its structure is more similar to the rat brain transporter (VMATZ), than to 
the rat adrenal counterpart (VMATl). Unlike rat VMATl, bovine VMATZ appears to be expressed both in the adrenal medulla and the brain, as 
judged by Northern analysis. After modification/deletion of the seven amino acids at the N-terminus of the protein it was expressed in a functional 
form. The order of affinity of the bovine VMATZ transporter to substrates is: serotonin>dopamine = norepinephrine>epinephrine. Also, the 
recombinant bovine adrenal transporter is highly sensitive to tetrabenazine, in sharp contrast to the rat adrenal transporter. The findings indicate, 
therefore, a clear species variation in which structure and function of the bovine adrenal transporter esemble the rat brain protein, while its tissue 
distribution is distinct from both types of rat proteins. In addition, the predicted protein sequence is identical to the experimentally determined 
N-terminus sequence of the purified vesicular amine transporter [Stern-Bach et al. (1992) Proc. Natl. Acad. Sci. USA 89, 973%9733]. 
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1. Introduction 
Classical neurotransmitters are stored in synaptic ves- 
icles and storage organelles of synaptic terminals and 
secretory cells. Transport and storage of the monoam- 
ines serotonin, dopamine, norepinephrine, epinephrine, 
and histamine in a variety of cells are catalyzed by vesic- 
ular monoamine transporters (VMATs). In bovine adre- 
nal chromaffin granules vesicular transport has been 
found to depend on a proton electrochemical gradient 
generated by the vesicular H’-ATPase and to involve the 
exchange of two lumenal protons with one cytoplasmic 
amine [14]. Transport is inhibited by a wide array of 
compounds, best represented by reserpine and tetrabena- 
zine. The two inhibitors interact with the transporter in 
distinct ways. Reserpine binds at the site of amine recog- 
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nition and its binding is accelerated by the imposition of 
a proton electrochemical gradient [5,6]. In contrast, 
tetrabenazine binds at a different site since its binding to 
the transporter is inhibited only by high substrate con- 
centrations [6]. Since transporters from different tissues 
accumulate the various amines with similar affinities and 
they display practically identical pharmacology, it has 
been proposed that either identical or closely resembling 
proteins catalyze the transport in all the tissues. 
Using the approach of cloning by functional expres- 
sion, the cDNA sequences for two distinct rat amine 
transporters have been obtained [7,8]. VMAT2 (previ- 
ously termed SVAT for synaptic vesicle amine trans- 
porter and VMATl) is found predominantly in brain, 
while VMATl (previously termed CGAT for chromaffin 
granule amine transporter) is found predominantly in 
the adrenal chromaffin granule. Tetrabenazine has been 
shown to be roughly 30-fold more effective at inhibiting 
the bovine adrenal transporter relative to that of the 
recombinant VMATl, suggesting an important species 
difference which should be elucidated. 
We have used oligonucleotide primers derived from 
the VMAT sequences to clone a cDNA predicted to 
encode the bovine chromaffin granule amine trans- 
porter. We find, surprisingly, that its structure is more 
similar to the rat brain transporter (VMAT2), than to the 
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rat adrenal counterpart (VMATl). However, its distri- 
bution does not resemble either type. Bovine VMAT2 
appears to be expressed both in the adrenal medulla and 
the brain, as demonstrated by Northern analysis. The 
affinity of the expressed bovine VMAT2 transporter to 
serotonin, dopamine and epinephrine is similar to those 
determined in membrane vesicles from bovine adrenal 
chromaffin granules [9-111 and in proteoliposomes re- 
constituted with the purified transporter [12]. Also, the 
recombinant bovine adrenal transporter is highly sensi- 
tive to tetrabenazine. In addition, the predicted protein 
sequence is identical to the experimentally determined 
N-terminus sequence of the purified vesicular amine 
transporter [ 12,131. Furthermore, modification/deletion 
of the seven amino acids at the N-terminus of the protein 
does not impair transport activity. 
2. Materials and methods 
2. I. Materials 
Taq polymerase was purchased from Fisher-Promega nd all other 
DNA modification and restriction enzymes were from New England 
Biolabs, Gibco-BRL, or Boehringer-Mannheim. Sequenase sequencing 
kits were purchased from US Biochemical Corp. Blotting media were 
from either Schleicher & Schuell (nitrocelhrlose), MS1 (Nytran), or 
DuPont (GeneScreen Plus). All radiochemicals were from NEN. Ol- 
igonucleotide synthesis reagents were from ABN. All other reagents 
were reagent grade or better. 
2.2. cDNA cloning, sequencing, and sequence analysis 
10 ng of DNA from a bovine adrenaimedulla cDNA library (1.54.5 
kb cDNA inserts) in LambdaZAP [14] was used as template in PCR 
reactions with primers based on comparisons with the existing rat 
VMATs cDNA sequences [7,8]; one sense-oriented primer AT61S (5’- 
TGCTGTACGAGTTTGTGG-3’. startine at nucleotide nosition num- 
ber 998) of VMATZ was used with anti&se-oriented phmer AT288A 
(5’-ACATGGTCTCCATCATCC-3’, starting at nucleotide number 
1256) of VMAT2. The final PCR amplification product produced a 
predominant 249 bp fragment. This fragment was sub-cloned into the 
EcoRV site of the Bluescript SK(-) vector and the DNA sequence from 
several clones was determined. A promising clone whose sequence 
showed significant identity with the VMAT2 and VMATl sequences 
was then radio-labeled by PCR amplification 1151 and used to screen 
2.5 x 10’ plaques of the same library as above, using standard hybridi- 
zation conditions [16]. Subsequent o cloning, super-infection with 
VCSM13 helper bacteriophage was used to excise the Bluescript SK(-) 
plasmid containing inserts. All DNA sequencing was performed by the 
dideoxy method as described on double-stranded plasmid DNA. Com- 
puter analysis was performed using DNANALYZE [17] and Clone and 
Align software from Scientific and Educational Software. The bovine 
amine transporter DNA sequence has been submitted to GenBank and 
has been given Accession No. U02876. 
2.3. Construction of a functionally expressing clone 
Two primers were synthesized, based on Bll-1D clone, in order to 
excise the coding sequence of the bovine vesicular monoamine trans- 
porter. The sense primer, P77, starting at nucleotide #77 of the Bl I-1D 
clone, and contains an EcoRI site (S’-ATGGGAATTCTGCTCCGC- 
CGGCTTCAG-3’). The antisense primer, RP1633, starting at nucleo- 
tide #I633 and contains a SnaBI site (5’~CGTACGTATTAGGTCA- 
TTGGAGGACT-3’). Following PCR reaction, the 1550 by-product 
was purified from the gel by QIAEX kit (Qiagen, Germany), cut by 
EcoRI and SnaBI and purified again as above. This fragment was 
cloned into a pTM1 vector [18] (a generous gift from Orna Elroy-Stein) 
which was prepared for ligation by EcoRI and StuI restriction endonu- 
clease cutting, and purified from agarose gel. Correct ligation yielded 
a 6.9 kbp vector in which translation of the bovine amine transporter 
starts at the ATG site of the vector and uses the first 3 amino acids of 
the vector, and then proceeds to amino acid #8 of the bovine trans- 
porter, thus truncating the original 7 amino acids from the amino 
terminal of the protein. 
2.4. Northern blot analysis 
Poly(A)-selected RNA was isolated from flash-frozen adrenal medul- 
lae, brain cortex, brainstem and liver as described [14]. RNA was 
denatured in 50.7% formamide and separated by electrophoresis 
through 1% agarose gels in 0.22 M formaldehyde. Capillary transfer to 
GeneScreen Plus membrane was performed for 12 h in a buffer contain- 
ing 0.025 M NaPO,, pH 6.5. The membrane was baked at 80°C for 2 
h, pre-hybridized under standard conditions, and then probed by incu- 
bation in the same buffer containing double-stranded DNA probe at 
approximately lo6 cpm/ml, 10’ cpm/pg. The probe was labeled with 
[“P]dATP by PCR amplification [i 51. Hybridization was done at 42” C, 
in 50% formamide. 10% Dextran-sulfate. 1% SDS. 0.8 M NaCl. 
Washing was for 30 min at 55°C in 2 k SSC, 1% SDS, once. 
2.5. Growth of cells. transfections and transport assays 
The protocol for functional expression of bovine VMAT2 was essen- 
tially as described by Erickson et al. [8]. CVl cells grown in 24-well 
plates (2.5 x lo5 cells per well) were infected with recombinant vaccinia 
virus encoding bacteriophage T7 DNA polymerase [19] for 30 min and 
then transfected with the plasmid (1.8 pg DNA) using 6.4 pg Transfec- 
tion reagent per well (Dotap-Boehringer). After 18-20 h cells were 
rinsed with uptake buffer containing 110 mM potassium tartrate, 5 mM 
glucose, 0.2% BSA, 5 mM MgCI,, 1 mM ascorbic acid, 10pM pargyline 
and 20 mM PIPES at pH 7.4. The cells were permeabilized for 10 min 
at 37°C in uptake buffer containing 10 PM digitonin. The medium was 
removed and replaced with fresh buffer without digitonin containing 
5 mM Mg-ATP and the corresponding tracers and/or inhibitors as 
indicated for the specific experiments. 
3. Results and discussion 
3.1. cDNA cloning 
A 249 bp radiolabeled AT-related PCR product (see 
section 2) was used to probe approximately 2.5 x lo5 
plaques from the same cDNA library at high stringency. 
Thirty-two hybridizing clones were identified and ex- 
cised from LambdaZAP, and both 5’- and 3’-end DNA 
sequences checked for each clone. Of these, 21 were 
found to belong to a family of cDNA’s most closely 
related to the previously-identified VMAT2 sequence [7] 
at their 5’-ends and termed b-VMAT2 to denote the 
bovine amine transporter and the higher similarity to rat 
VMAT2 (SVAT). These clones were grouped into three 
different sets by virtue of the lengths of their 3’-ends. The 
clone with the longest S-end sequence (1 1-1D) was used 
to determine its complete DNA sequence. Of the remain- 
ing 20 clones, 19 were found to have identical 3’-ends 
which were longer than that of clone 11-lD, and the 
complete DNA sequence was determined for the longest 
clone from this set, 4-1A. The DNA sequence from this 
clone was found to be identical to that of 1 1-1D except 
for an 87 1 bp 3’-extension; its 3’-end was identical to that 
of 18 of the other b-VMAT clones. The last clone, 2-4A, 
identical in all other respects, was found to have an 
alternative poly-adenylation site at position 1932. 
3.2. Predicted amino acid sequence 
The b-VMAT predicted amino acid sequence is pre- 
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sented in Fig. 1. The 2726 bp cDNA is predicted to 
encode a protein of 517 amino acids with a p1 of 5.34 and 
calculated molecular mass of 55,690. The sequence is 
predicted to begin at nucleotide number 56, for the N- 
terminal sequence previously determined for the amine 
transporter protein, LSELALLRRLQESRFSRXLILF- 
IVFLXL [ 12,131. Thus sequence agrees in all but the one 
underlined position of the b-VMAT2-predicted amino 
acid sequence (F+H). This position would also agree 
well with the predicted starts for both the VMATI and 
VMAT2 predicted proteins. An internal peptide se- 
quence reported at the same time, DPQILIAKG, resem- 
bles the peptide sequence running between &dues 294 
and 302 of the b-VMAT protein sequence xcept for the 
underlined positions. Repeated sequencing attempts 
with multiple clones have confirmed the clonal DNA 
sequences, suggesting that the discrepancies are either 
due to peptide sequencing errors or the presence of an- 
other protein in the bovine adrenal medulla. When sub- 
jected to the Eisenberg moment plot analysis [20], the 
b-VMAT protein sequence was predicted to contain 12 
trans-membrane segments, indicated by overlining in 
Fig. 2. These regions agree well with the predicted trans- 
membrane domains for the rat VMAT proteins. Overall 
identity of the bovine VMAT protein sequence was 
87.8% and 62.9% with the rat VMAT2 and VMATl 
protein sequences, respectively. The region between 
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trans-membrane domains I and II shows a much greater 
sequence divergence with the previously-cloned amine 
transporter predicted proteins than the rest of the protein 
(identities of 57.6% for VMAT2 and 30.4% for VMATl). 
Because of its higher similarity to rat VMAT2, the bo- 
vine clone is defined also as VMAT2 type. 
3.3. Tissue distribution 
Northern analysis of tissue distribution in rat indi- 
cated that VMAT2 was present in brain but not in the 
adrenal gland, while VMATI was present in the adrenal 
but not in brain [7]. Northern blot analysis with the 
bovine VMAT2 cDNA indicated that the adrenal me- 
dulla contains a cognate mRNA population of about 4.5 
kb in size (Fig. 3, lanes D). A related mRNA is detected 
also in the bovine brain stem and cortex, although in 
much lower amounts (Fig. 3, lanes B and C). The expo- 
sure needed to visualize the brain message is 50-fold 
higher than that for the adrenal. Under these conditions, 
a smaller size mRNA of 1700 bp is detected in brain 
cortex together with a bigger size mRNA (6500 bp) pres- 
ent in adrenal and brainstem. No cross-hybridizing ma- 
terial is detected in liver. 
The results described above suggest that the major 
bovine adrenal transporter is highly similar to the trans- 
porter found in the rat central nervous system rather 
than to the rat adrenal transporter. However, its distri- 
CTCGGMGCTTCGGCCCAAGCACCCCCACCACCCCCACC 
MALSELALLRRLOESRBSRKLI 
CCTGTTWLTM;n;TTCCTCGCCCrCCTGC~CTffiA~~TGCTGCTCA~TTG~TCCC~T~TCCCG~TTACT~TA~G~TTGA~~AG~A~CT~~~TC~AC 
LFIVFLALLLDNMLLTVVVPIIPSYLYSIEEiEF.DALEIQT 
CGCCMGCCCGCCCTCACACCCTCCCCCCCCCCCM;CTTCCT CAGGGGGCGCTGGTGCA 
AKPGLTASAPGSPQNIFSYYDNSTMVTGNSTDELQGALVH 
TCAGCCCACCACGCAGCACATGGCCACTMCTM;rCCTCffiCCTCTTC~AC~TCC~TG~A~ACCTCCTGM~AGMTGT~TC~CTGCTGTTTGCCTCG~ 
EATTQEMATNSSSASSDCPSEDKDLLNENVQVGLLFASKA 
CACTGTCCACCTCCTWLCCC~TTCATA~ACTGTTGAC~~MTT~CTACC~TTCC~TGTTTA~ATTCTG~T~TGTTTATCT~~GTTATGTTCGCCTT~C 
TVQLLTNPFIGLLTNRIGYPIPnFTCFCInFISTVnFAFS 
CCGCACCTACGCCTTCCTGCTCATCGCC~TCCAC 
RTYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGN 
CGCCATGGCGATCGCCCTCCCACCCCAT~TCCTAGT~CCCCCCCTTT~~TGTGC?GTA~~TT~T~MGA~~TCCGTTCCT~TCTT~CTGCCCT~T 
AHGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAALV 
GCTCTTCCATCGAGCCATTCCTCTTTGTGCTCCACCCC 
LLDGAIQLFVLQPSRVQPESQKGTPLTTLLRDPYILIAAG 
GTCWLTCTGCTTCGCAMCATGCCGATTCCCATGCTGGAGCT 
SICFANMGIAMLEPALPIUMMETMCSEKUQLGVAFLPASV 
CTCTTATCTWLTTGGMCCMTGTTTTT~ATCCTCG~~~~~AT~CTTTG~CTCTTCT~MTGATMTTGTC~MTG~~TTTTATGTATTCCTCTTG~ 
SYLIGTNVFGILAiiKHGRULCALLGl4IIVG?fSILCIPLAK 
AMCATCTACGCACTCATAGCTCCCMCTTTCGAGTTffiTTT 
NIYGLIAPNFGVGFAIGHVDSSMMPIMGYLVDLREVSVYG 
GAGCGTGTACGCWLTTGCCGATGTTCCCTTTTGTA~ATATGC~T~TCCTTCTGCT~T~CTATCG~~~TT~ATTTC~T~CT~TGA~TTATT~MTMT 
SVYAIADVAFCMGYAIGPSAGGAIAKAIGFPULMTIIGII 
TGATATTCTTTTTGCTCCTCTCTGCTTTTTTCTTCGAAGTCCACCTGC-MG ~T GCTATCCTCATLXATCACAACTGCCCCATTAAAACAMAA TGTACACGCAGMCAG 
DILFAPLCFFLRSPPAKEEKMAILMDENCPIKTKMYTQNS 
CAGCCAGTCGCATCCGATAGCTCACCATGMGMTCTG~GTGACTG~ACCCG~TCCTC~GTACCTMTTGTAT~GTGTTTC~GTG~TGACT~TC~GMCTGT 
SQSEPIGEDEESESD-*- 
CTTAGTCATACCACTCATCCCTCCTGAAAGTCATACMCCA AAAAAGCAGCTTTTCTAGGGGTTTGTA 
l 
TIUATAGTGT;AAMCTTTATTTTATGTATTTGATTTTATT~TATTATA~TAT~TTTTGACG~TATAG~T~TCTAT~TATT~MTC~T~TATMTTTTTTA 
l 
ACTTACATTCACAA&ACCTGGGC~ GTCTTATATTTTTTTCTGMTATTGCTMTGAGTGTTTAMGA 
AGTCrCAAMGAGACTCMCTA~TATATT~T~TGACACTGM~TTACTGMCTT~MTTA~GT~ACCTGM~~~TTT~MTGC~CACCC~~~ 
GCTGAAMCAGTCACCCCTTCTCTCTGATTTCACGTCC CTCTGCATGTAAGTGGACCCAT 
GCAGTT~TCATGTTGTTCGGCGGTTGTA~ATCM 
CTCAGTTCCCATTAGTTTTCTAX;TMTCACCTACCTCCMC 
TGTTCTG~WLGAG-GCACCCACATATATACTTATGM~CTAG~CTTTCCCTTTC~ATA~TACTTGTCTTACC~ATGA~ACTGAG~G~~CCTTATACTA 
TCAGCATTGTTGMGCATGATGAGATATACCT CTMTAGCTGCTGTGATGTGq, 
120 
( 22) 
240 
( 62) 
360 
(102) 
480 
(142) 
600 
(182) 
720 
(222) 
840 
(262) 
960 
(302) 
1080 
(342) 
1200 
(382) 
1320 
(422) 
1440 
(4621 
1560 
(502) 
1680 
(517) 
1800 
1920 
2040 
2160 
2280 
2400 
2520 
2640 
2729 
Fig. 1. cDNA and predicted amino acid sequence for b-VMAT2. The single letter amino acid code is used throughout. Predicted peptide sequences 
corresponding to determined aminoacid sequence [13] are indicated by underlining. The positions of the two alternative poly-adenylation sates are 
indicated by underlining and an asterisk posrtioned above each nucleotide. 
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II III Iv 
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.---TL.QTA....V..A.AVP.............................I.................I.A......V..I.....SS.................. 
.P.GQS.K..STQHTVANTTVP.......R.........................................A...............ss.................. 
TIPPP.T..--------..WKNN.LPCIEF.EE...RI.I......LH...V...V.P.......B....V..M...L..L.....G...L.FV..T.......F. 
V VI VII 
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. . . . . . . . . . . . . . . . . . ..v............................................................ . . . . . . . ..K................ 
. . . . . . . . . . . . . . . . . ..K........................................................... . . . . . . . . ..K................ 
. . ..L.........m...R..........L.L...A.....M......SS...I..F.A.....L..CI.U..K.S...~..S.L...K.....V......L... 
VIII IX X 
CIAMLEPALPI~~CS~WQLGV~L~A~S~IGT~GI~R~~LG~IVG~ILCIP~IYGLI~~GVGF~G~S~I~~~LR 
. . . . . . . . . . . . . . . . . ..R............I.......I...................... V......F.................................... 
. . . . . . . . . . . . . . . . . ..R............I.......I..................V...I......F..................F................. 
.V.I...T......Q....PE....L.......A......L..V..N.... . ..S.V..VA..I.L.LCTSGSQYFWSYU..A.L..........L........... 
( 95) 
( 95) 
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(306) 
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(413) 
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(418) 
bVMAT2 
XI XII 
WSWGSWAIMIVAF~YAIGPSAU;AIAXAICFPWLE(IIGIIDILFAPLCFFLRSPPA~I~~CFIK~T-QNS~S~IGE--DEESESD (517) 
hVKP.TZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..-..NI..Y....--....... (514) 
rVMAT2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..A.............................R....-..~..Y...D--....... (515) 
rVMAT1 .T...............VPF.....T..V.VQV.......V...T.N.IY....C..QN.......R...-SQE..TE.Q...F.KPTKAF.L..NS.DP.SGE (521) 
Fig. 2. Alignment of the bovine, rat, and human vesicular monoamine transporters predicted protein sequences. b-VMATZ = bovine chromaffin cell 
amine transporter; rVMAT2 = rat ‘synaptic vesicle’ amine transporter [8]; rVMAT1 = rat ‘chromaffin granule’ amine transporter [7]; hVMAT2 = 
human ‘synaptic vesicle’ amine transporter [25,26]. Identities in the sequence are indicated by periods, differences by the indicated residue, and gaps 
by hyphens. Overlining indicates the positions of predicted transmembrane segments. 
bution resembles neither of them. This is a surprising 
species difference and its basis will be studied in depth. 
The possibility that there are two types of transporters 
in the adrenal gland has been suggested from previous 
biochemical studies in which two isoforms with different 
p1 values were identified [12]. We have performed re- 
peated screens and failed to find alternative VMAT 
forms, but we cannot rule out at present the possibility 
that a VMATl-type of transporter is present in the bo- 
vine adrenal medulla at very low frequency. 
A B C,D 
-28S- 
-18S- 
ABCD 
Fig. 3. Northern analysis. Poly(A)-selected RNA extracted from bovine 
adrenal medulla (A), brain cortex (B), brainstem (C) and liver (D) was 
separated and a Northern replica of the gel probed with radiolabeled 
cDNA. 
3.4. Transport catalyzed by bovine VMAT2 is tetrabe- 
nazine sensitive 
Transport of [3H]dopamine into CVl cells was meas- 
ured following infection with vaccinia virus and transfec- 
tion with the cDNA coding for VMAT2. Cells were per- 
meabilized with digitonin as described by Erickson and 
collaborators [8]. Since the original clone Bl 1-1D did not 
yield significant transport activity, several approaches 
were taken in order to yield a functional protein. The 
successful strategy entailed modification of 7 amino 
acids from the amino-terminal of the transporter: dele- 
tion of four amino acids together with replacement of the 
two amino acids adjacent to the ATG. The modified 
protein start at the sequence MGILL, as compared to the 
original cDNA clone Bl l- 1 D which predicts the se- 
quence MALSDLVLL. The engineered cDNA (con- 
structed by PCR as described in section 2) was inserted 
into pTM1 vector [18], which was used to transfect CV-1 
cells. 
When cells were transfected with such a construct, 
[3H]dopamine is accumulated in a time-dependent fash- 
ion and uptake is maximal at 5 min. Transport is practi- 
cally completely inhibited in the presence of the proton 
ionophore CCCP as expected from the well known prop- 
erties of VMAT (Fig. 3A). The findings suggest hat, as 
previously reported for the rat clones expressed in CVl 
cells and CHO fibroblasts, the bovine VMAT is also 
targetted to acid subcellular organelles and exchanges 
lumenal protons for cytoplasmic monoamine. 
The vesicular monoamine transporters are known for 
their ability to catalyze accumulation of a variety of 
monoamines. We therefore tested the ability of trans- 
fected cells to transport [3H]serotonin. Indeed trans- 
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fected cells accumulate [3H]serotonin in a time-depend- 
ent, CCCP-sensitive fashion (Fig. 3B). Transport of both 
monoamines is inhibited by reserpine at 5,uM (Fig. 3A 
and B). No accumulation of either monoamine is ob- 
served in untransfected cells or cells transfected with the 
vector alone (data not shown). 
Measuring the initial rates of uptake (10 min) into the 
organelles we have determined [3H]dopamine’s K,,, and 
tested the effect of different substrates and inhibitors on 
[3H]dopamine uptake. Reserpine, tetrabenazine and ket- 
anserin completely inhibit transport in a dose dependent 
manner with Ko5 at 1 nM, 0.06 and 5 PM, respectively. 
The potency of the three inhibitors is in excellent agree- 
ment with previous studies using membranes from bo- 
vine adrenal chromaffin granules [12,21-231. However, 
the sensitivity to tetrabenazine is in sharp contrast o that 
reported for the rat VMATl, the chromaffin granule 
monoamine transporter. Rat VMATl shows a reduced 
sensitivity to the drug (K, 5 = 4 PM). 
Among the substrates, serotonin shows the highest 
affinity to bovine VMAT2 (K,, 5 = 1.2 PM); dopamine 
displays a lower affinity (Km = 9 PM; data not shown) 
very similar to norepinephrine (K,, 5 = 7 PM) and higher 
than epinephrine (K,,, = 20 PM). The relative affinities 
of the four substrates is in very good agreement with 
those measured in studies using membrane vesicles from 
bovine adrenal chromaffin granules [9-l l] and in prote- 
oliposomes reconstituted with the purified transporter 
[W 
___-_A___________ 
A A 
0 5 10 15 20 25 
4. Conclusions 
The studies presented in this communication report 
the cloning and sequencing of a bovine adrenal vesicular 
monoamine transporter (b-VMAT2) which after modifi- 
cations at its amino terminal could be expressed in a 
functional form in CV-1 cells, and its transport proper- 
ties were characterized. It still remains to be elucidated 
whether the non-functional form of the original isolated 
clone is due to a cloning artifact or the presence of se- 
quences upstream of the translation initiation codon, 
which can negatively affect its expression in CHO and 
CV-1 cells. In terms of substrate preference, the affinity 
of the transporter was the highest for serotonin, very 
similar for dopamine and norepinephrine and the lowest 
for epinephrine. The affinity for serotonin is practically 
identical to that reported for the purified transporter [121 
and about five times higher than those reported for mem- 
brane vesicles [9-l 11. The affinities for dopamine and 
epinephrine are about two to three fold higher than those 
reported in membrane vesicles. These small differences 
may just reflect the fact that the protein is expressed in 
an heterologous cell and that transport is assayed quite 
differently. On the other hand, since the affinity for sero- 
tonin is identical to the one observed using prote- 
oliposomes reconstituted with the purified protein but 
higher than that observed in membranes it could reflect 
the possible existence in the native adrenal membranes 
of two distinct transporters with different affinities. 
B 
0 5 10 15 20 25 
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Fig. 4. [3H]Dopamine and [3H]serotonin uptake in permeabilized CVl cells transfected with b-VMAT2. CVI cells were treated as described in section 
2. Transport was assayed after incubation with [‘Hldopamine (15 nM, 32.2 Ci/mmol) (panel A) or [‘Hlserotonin (0.2 PM, 25.7 Ci/mmol) (panel B) 
for the indicated time periods. Experiments were performed in the presence of 10 PM CCCP (o), 5 PM reset-pine (A) or with no further 
additions (0). 
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Fig. 5. Effect of inhibitors and transport susbtrates on [‘Hldopamine uptake by permeabilized CVl cells transfected with b-VMAT2. CVl cells were 
treated as described in section 2. Transport was assayed after incubation with [‘Hldopamine (15 nM, 32.2 Ci/mmol) for 10 min in the presence of 
the indicated concentrations of reserpine (m), tetrabenazine (o), ketanserine (A), serotonin (0). norepinephrine (0) and epinephrine (0). All the 
experiments were carried on in triplicates and repeated at least twice. 
These findings would be in line with the fact that two 
proteins with distinct p1 have been identified during pu- 
rification of the bovine VMAT [12]. In any case, the one 
purified is most likely identical to the clone reported in 
this work since the predicted N-terminus from the cDNA 
is identical to the experimentally determined one [13]. 
The purified protein represents at least 60% of the total 
activity measured in membrane vesicles from bovine ad- 
renal chromaffin granules [ 121. 
Transport catalyzed by b-VMAT2 is sensitive to reser- 
pine, ketanserin and tetrabenazine at concentrations 
practically identical to those reported in studies of mem- 
brane vesicles from bovine adrenal chromaffin granules. 
This is in contrast to the previous report for the rat 
adrenal vesicular monoamine transporter (r-VMATl), 
which is about 30-fold less sensitive to tetrabenazine 
[7,24]. In addition, the transporter from bovine adrenal 
shows a higher similarity to the rat CNS type, VMAT2 
(87.8%), rather than to the rat adrenal type, VMATl 
(62.9%). However, while message for rat VMAT2 is not 
found in the rat adrenal gland, message for bovine VMAT2 
is found predominantly in the adrenal and to a lesser 
extent in the brain. The differences in distribution and in 
sensitivity to tetrabenazine reflect an important species 
variation. We do not know yet whether this is an intrinsic 
difference or reflect some response of the animals to 
treatment before slaughtering and tissue collection. 
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Note added in proof 
After this paper was accepted, a report with a practically identical sequence by Krejci et al., appeared in FEBS Letters 
335 (1993) 27-32. 
